TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PF-00489791 For The Treatment Of Raynaud's

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Active Raynaud's Phenomenon~* Stable disease and medication requirements over the previous two months~* For Secondary Raynaud's Phenomenon subjects, a diagnosis of scleroderma using the American College of Rheumatology criteria or by the presence of at least 3/5 features of CREST syndrome~* both sexes~Exclusion Criteria:~* Uncontrolled hypertension, diabetes mellitus, angina, or using oral nitrates~* Smoking within 3 months or smoking cessation using nicotine products~* Subjects currently taking sildenafil, tadalafil or vardenafil~* Subjects with ulnar arterial occlusive disease as shown by a modified Allen test~* Pregnant or breast feeding or considering pregnancy in next 4 months~* Participation in trial for investigational drug within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Secondary Raynaud 4 mg dose (period 1) (Type: EXPERIMENTAL): None
- Secondary Raynaud 4 mg dose (period 2) (Type: EXPERIMENTAL): None
- Secondary Raynaud 20 mg dose (period 1) (Type: EXPERIMENTAL): None
- Secondary Raynaud 20 mg dose (period 2) (Type: EXPERIMENTAL): None
- Primary Raynaud 4 mg dose (period 1) (Type: EXPERIMENTAL): None
- Primary Raynaud 4 mg dose (period 2) (Type: EXPERIMENTAL): None
- Primary Raynaud 20 mg dose (period 1) (Type: EXPERIMENTAL): None
- Primary Raynaud 20 mg dose (period 2) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary grade 3 or 4 malignant glioma of 1 of the following types:~  * Glioblastoma multiforme~ * Gliosarcoma~ * Anaplastic astrocytoma~ * Anaplastic oligodendroglioma~* Patients with recurrent disease whose original diagnostic pathology confirmed malignant glioma will not need re-biopsy~* Measurable recurrent or residual primary disease on contrast-enhanced MRI or CT scan~* Failed ≥ 1 prior chemotherapy regimen (with or without radiotherapy)~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* Hematocrit \> 29%~* Absolute neutrophil count \> 1,500/mm\^3~* Platelets \> 125,000/mm\^3~* Serum SGOT and bilirubin \< 1.5 times upper limit of normal~* Creatinine \< 1.5 mg/dL~* Urine protein:creatinine ratio ≤ 1.0~* Blood pressure ≤ 150/100 mmHg~* No unstable angina~* No New York Heart Association class II or greater congestive heart failure~* No myocardial infarction within the past 6 months~* No stroke within the past 6 months~* No clinically significant peripheral vascular disease~* No evidence of bleeding diathesis or coagulopathy~* No significant traumatic injury within the past 28 days~PRIOR CONCURRENT THERAPY:~* At least 4 weeks must have elapsed since prior chemotherapy or radiotherapy unless there is unequivocal evidence of tumor progression~* At least 6 weeks since prior surgical resection~* No previous major surgical procedures or open biopsies within 28 days prior to study entry~* No previous minor surgical procedures, fine needle aspirations, or core biopsies within 7 days prior to study entry~* No anticipated need for major surgical procedures during the course of the study~* No concurrent aspirin, non-steroidal anti-inflammatory drugs, or clopidogrel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18, with chronic genotype 1 HCV infection~* HCV treatment-experienced, including patients who have previously failed a nonstructural protein (NS)3/4A protease inhibitor plus pegylated interferon (PEG)/RBV regimen~* HCV RNA \> 10,000 IU/mL at screening~* Cirrhosis determination; a liver biopsy may be required~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Coinfection with HIV or hepatitis B virus~* Current or prior history of clinical hepatic decompensation~* Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers)~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 12 Weeks (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC for 12 weeks.
- LDV/SOF+RBV 12 Weeks (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC plus RBV for 12 weeks.
- LDV/SOF 24 Weeks (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC for 24 weeks.
- LDV/SOF+RBV 24 Weeks (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC plus RBV for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Age 18 years to 60 years~* Average to low daily physical activity~* Ability to ambulate for 75 meters without assistive devices~* Diagnosis of BMD confirmed by at least one the following:~  * Dystrophin immunofluorescence and/or immunoblot showing partial dystrophin deficiency, and clinical picture consistent with typical BMD, or~ * Gene deletions test positive (missing one or more exons) of the dystrophin gene, where reading frame can be predicted as 'in-frame', and clinical picture consistent with typical BMD, or~ * Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, or other mutation resulting in a stop codon mutation) that can be definitely associated with BMD, with a typical clinical picture of BMD, or~ * Positive family history of BMD confirmed by one of the criteria listed above in a sibling or maternal uncle, and clinical picture typical of BMD.~* Nutritional, herbal and antioxidant supplements taken with the intent of maintaining or improving skeletal muscle strength or functional mobility have been discontinued at least 2 weeks prior to screening (daily multivitamin use is acceptable).~* Hematology profile within normal range~* Baseline laboratory safety chemistry profile within normal range~* No plan to change exercise regimen during study participation~Exclusion Criteria:~* Currently enrolled in another treatment clinical trial.~* History of significant concomitant illness or significant impairment of renal or hepatic function.~* Use of regular daily aspirin or other medication with antiplatelet effects within 3 weeks of first dose of study medication.~* Regular participation in vigorous exercise.~* Symptomatic heart failure with cardiac ejection fraction \<25%

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treatment with Epicatechin (Type: EXPERIMENTAL): Purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients older than 40 years of age with stage I hypertension~Exclusion Criteria:~* low life expectancy~* other indications for the use of diuretics, such as cardiovascular disease~* intolerance to the study drugs~* pregnancy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chlorthalidone plus amiloride (Type: ACTIVE_COMPARATOR): Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily for 18 months
- losartan (Type: EXPERIMENTAL): Oral losartan up to 100 mg daily, once a day, for 18 month

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Men and non-pregnant, non-breastfeeding women~* 18 years or older~* Scheduled for knee replacement surgery~Key Exclusion Criteria:~* hereditary or acquired bleeding disorders~* clotting disorders~* bleeding or high risk for bleeding~* drugs that affect bleeding or coagulation~* need for ongoing parenteral or oral anticoagulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A1 (Type: ACTIVE_COMPARATOR): + placebo
- A2 (Type: EXPERIMENTAL): + placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study: Vaginal Promestriene Use, Fractional CO2 LASER and Radiofrequency in the Vaginal Atrophy Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Age equal or superior to 40 years and under 65 years~* Clinical menopause - last menstrual period from 1 to 5 years from the date of recruitment~* FSH measurement\> 25 IU / ml, estrogen \<20 æg / ml~* Patients with vaginal atrophy and clinical and / or sexual symptoms~* Patients without hormonal treatment for at least five years~Exclusion Criteria:~* Whole Hymen~  * Altered oncology cytology of the cervix and / or vagina~ * Vaginal infections~ * Connective tissue diseases~ * Immunosuppression~ * Coagulation change~ * Diabetes Mellitus~ * Thyroid diseases~ * Use of systemic or local feminine hormones~ * Use of other substances with estrogenic properties

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fractional CO2 LASER (Type: ACTIVE_COMPARATOR): Vaginal fractional CO2 LASER 3 sessions applications
- Microablative fractional radiofrequency (Type: ACTIVE_COMPARATOR): Vaginal Microablative fractional radiofrequency 3 sessions application
- Promestriene Vaginal (Type: ACTIVE_COMPARATOR): Promestriene vaginal use during 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 18 years or older~* Documented HIV-1 infection~* Stable PI regimen for at least 8 weeks prior to screening~* Plasma viral load at screening above 1000 HIV-1 RNA copies/ml~* Prior use of more than 1 NRTI for at least 3 months~* Prior use of one or more NNRTIs as part of a failing regimen~* At least 1 primary PI mutation as defined by the IAS guidelines~* Treatment with at least 1 PI for a total of at least 3 months~* Patient has given informed consent~Exclusion Criteria:~* Presence of any currently active AIDS defining illness except stable cutaneous Kaposi's Sarcoma and Wasting syndrome due to HIV infection~* Current or past history of alcohol and/or drug abuse which, in the investigator's opinion, would compromise the subject's safety or compliance to the study protocol procedures~* NNRTI as part of therapy at screening~* Patients on a treatment interruption at screening~* Patients for whom an investigational antiretroviral therapy is part of the regimen at screening or the use of any non-antiretroviral investigational agents 90 days prior to screening~* Hepatitis A, B, or C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): TMC114/rtv 400mg TMC114/100mg rtv once daily
- 005 (Type: NO_INTERVENTION): Control Group Control Group, no intervention
- 004 (Type: EXPERIMENTAL): TMC114/rtv 600mg TMC114/100mg rtv twice daily
- 003 (Type: EXPERIMENTAL): TMC114/rtv 400mg TMC114/100mg rtv both twice daily
- 002 (Type: EXPERIMENTAL): TMC114/rtv 800mg TMC114/100mg rtv once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese healthy men or women aged 18 to 55 years old at screening (inclusive）;~* Serum LDL-C concentration between 1.8 mmol/L and 4.9 mmol/L (inclusive）at screening;~* Body mass index between 19 and 28 kg/m2 (inclusive);~* Willing to maintain the current regular diet and physical activity;~* Female subjects and male subject's partner who could become pregnant should take effective contraceptions during the treatment period and 6 months after dosing;~* Without any medical history of serious diseases;~* Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent.~Exclusion Criteria:~* Breast-feeding or pregnant women;~* History of allergic reaction;~* Previously received any anti-PCSK-9 treatment;~* Vital signs, physical examination, clinical laboratory test, 12-lead ECG, and chest X-ray are abnormal with clinical significance;~* Not willing to stop intense physical activities (such as weight lifting or long-distance running) before 72 hours of the scheduled visits;~* Any hospitalization within one month before screening, or major surgery within six months before screening, or any other unstable medical condition;~* Received an investigational chemical agent within 30 days before dosing；~* Received an investigational biological agent within 90 days before dosing；~* Use of medications including over-the-counter medication within 14 days or less than 5 half-lifes of the agent;~* Use of herb,vitamins or nutraceutical in order to alter serum lipids;~* Positive screen of hepatitis B surface antigen, hepatitis C virus, human immunodeficiency virus or syphilis infection at screening；~* History or clinical evidence of alcohol or drugs of abuse within 12 months before screening;~* With any consumption of alcohol and caffeinated beverages within 72 hours prior to and during the trial;~* Blood donations or blood loss 200 ml and more within 2 months before screening;~* History of organ transplantation or malignant tumor;~* Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- IBI306 (Type: ACTIVE_COMPARATOR): Subcutaneous or intravenous injection of a single dose of IBI306, dose level according to ascending dose design
- placebo (Type: PLACEBO_COMPARATOR): Subcutaneous or intravenous injection of a single dose of placebo, dose level according to ascending dose design

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nanofat in Post Burn Scars on the Face

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Post burn scars on the face~* Fitzpatrick skin types between 3 and 4~Exclusion Criteria:~* Hypertrophic scars~* Contractures~* Keloids

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alabama Community Healthy Marriage Initiative Evaluation Project for Couples

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* To be eligible for the AHRMEI Couples Evaluation Project, the applicant must be part of a couple (as defined by the couple) in which both couple members are applying to the program and that: both members of the couple are 19 years of age or older, both members of the couple can attend the majority of the class offerings.~Exclusion Criteria:~* Does not meet the inclusion criteria.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Couples Connecting Mindfully Curriculum (Type: EXPERIMENTAL): Receives the Couples Connecting Mindfully curriculum over a 6 week period.
- ELEVATE Curriculum (Type: EXPERIMENTAL): Receives the ELEVATE curriculum over a 6 week period.
- Control (Type: NO_INTERVENTION): No programming is offered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Identifying the Lung Intersegmental Plane by Iron Sucrose Injection Staining

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years ≤age ≤80 years~* The patient must be scheduled to undergo segmentectomy or combined subsegmentectomy.~* The patient must be willing and able to comply with all study requirements and have understood and signed the informed consent.~Exclusion Criteria:~* A known allergy to Iron Sucrose Injection~* The patients who have Iron overdose or iron utilization barrier Intra-operative founding of extensive pigmentation Silicosis or extensive carbon deposition in the lung.~* Patients who have not received segmental resection.~* Patients who converted to thoracotomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Iron Sucrose injection group (Type: EXPERIMENTAL): The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) through a butterfly needle into the bronchus of the targeting segment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. sign the informed consent~2. Aged 20-70 years~3. ovarian cancer patients, staged IIIB - C or above~3) ASA I - II~Exclusion Criteria:~1. tranexamic acid allergy~2. pregnancy and lactation~3. only lymph node metastasise~4. history of mental disorder, immune system disorder~5. history of epilepsy, dyschromatopsia~6. arrhythmia~7. history of renal insufficiency~8. thrombosis related disease~9. Hb \< 90 g/dL~10. using anticoagulant drugs (not including aspirin discontinuation 1 week~11. having participated in other clinical trials, or refusing to join the research.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- high dose TXA (Type: EXPERIMENTAL): TXA will be given as a 20mg/kg bolus followed by infusion of 5mg/ kg/hr per our anesthesia protocol
- low dose TXA (Type: EXPERIMENTAL): TXA will be given as a 10mg/kg bolus followed by infusion of 1mg/ kg/hr per our anesthesia protocol
- normal saline (Type: PLACEBO_COMPARATOR): saline will be given as a 4ml/kg bolus followed by infusion of 1ml/ kg/hr per our anesthesia protocolprotocol4ml/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete